Aditxt, Inc. ADTX
Set alert
At close · Oct 28
After hours · Oct 28, 4:00 PM ET
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.0002
- Prev close
- 0.001
- Mkt cap
- 997.98K
- Vol
- 9.76M
- Avg vol
- 17.01M
- EPS
- 25,450,100.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0001
- High
- 0.0018
- Forward P/E
- -0.02
- Beta
- 1.08
- Short ratio
- 0.16
- Inst. own
- 0.25%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Apr 2, 2024
- 50-d avg
- 0.5011
- 200-d avg
- 49.86
- 1y target
- 0.00
Key statistics
- Market cap
- 2.62M
- Enterprise value
- 7.76M
- Trailing P/E
- 0.00
- Forward P/E
- -0.02
- PEG ratio
- 0.00
- Price / sales
- 7.96
- Price / book
- 0.00
- EPS (TTM)
- 628.80
- Beta
- 1.08
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 329.74K
- Revenue growth
- -80.00%
- Free cash flow
- -13.26M
- Total cash
- 91.22K
- Total debt
- 8.04M
- Return on equity
- -3493.63%
- Shares outstanding
- 14.23M
- Short % of float
- 10.42%
- 50-day average
- 0.5011
- 200-day average
- 49.86
Analyst view
Consensus: none
Next earnings
Apr 2, 2024
Expected Apr 2, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 18, 2024 | Sep 1, 2024 | 0.00 | -111.07 | — | — |
| Aug 19, 2024 | Jun 1, 2024 | 0.00 | -167.60 | — | — |
| May 20, 2024 | Mar 1, 2024 | -133.20 | -365.60 | -232.40 | -174.47% |
| Apr 2, 2024 | Dec 1, 2023 | -17.14 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | -239.60 | -1,950.80 | -1,711.20 | -714.19% |
| Aug 14, 2023 | Jun 1, 2023 | -4,624.00 | -1,472.00 | +3,152.00 | +68.17% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 6, 2023 | HC Wainwright & Co. | main | Buy | Buy |
About Aditxt, Inc.
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aditxt.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on ADTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BNP PARIBAS SECURITIES CORPORATION NORTH AMERICA | Unknown | Sale | Sep 6, 2023 | 22,342 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 0.02% | 3,223 | 594 | Sep 29, 2024 |
| HRT Financial LP | 0.01% | 1,150 | 212 | Sep 29, 2024 |
| Two Sigma Investments, LP | 0.01% | 801 | 147 | Sep 29, 2024 |
| Jane Street Group, LLC | 0.01% | 765 | 141 | Sep 29, 2024 |
| IFP Advisors, Inc | 0.00% | 13 | 2 | Jun 29, 2024 |
| Stonex Group Inc. | 0.00% | 486 | 89 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.00% | 114 | 21 | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.00% | 372 | 68 | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.00% | 1 | 0 | Oct 30, 2024 |